Terms: = Breast cancer AND ER, estrogen receptor AND Clinical Outcome
728 results:
1. Tumor budding in breast carcinoma: A systematic review and meta-analysis.
Buch A; Khan U; Rathod H; Jain K; Dwivedi A; Rajesh A
J Cancer Res Ther; 2023 Oct; 19(7):1697-1713. PubMed ID: 38376268
[TBL] [Abstract] [Full Text] [Related]
2. Molecular features of luminal breast cancer defined through spatial and single-cell transcriptomics.
Yoshitake R; Mori H; Ha D; Wu X; Wang J; Wang X; Saeki K; Chang G; Shim HJ; Chan Y; Chen S
Clin Transl Med; 2024 Jan; 14(1):e1548. PubMed ID: 38282415
[TBL] [Abstract] [Full Text] [Related]
3. clinical characteristics and prognosis of primary small cell carcinoma of the breast: a propensity score-matched, population-based study.
Yin L; Yin AH; Pu CC
BMJ Open; 2023 Dec; 13(12):e073841. PubMed ID: 38097248
[TBL] [Abstract] [Full Text] [Related]
4. A controversial ER negative PR positive molecular subtype of breast carcinoma-Report of two cases.
Chandra S; Bhasin S; Saini S
Breast Dis; 2023; 42(1):315-318. PubMed ID: 37807774
[TBL] [Abstract] [Full Text] [Related]
5. estrogen receptor beta expression in triple negative breast cancers is not associated with recurrence or survival.
Takano EA; Younes MM; Meehan K; Spalding L; Yan M; Allan P; Fox SB; Redfern A; Clouston D; Giles GG; Christie EL; Anderson RL; Zethoven M; Phillips KA; Gorringe K; Britt KL
BMC Cancer; 2023 May; 23(1):459. PubMed ID: 37208678
[TBL] [Abstract] [Full Text] [Related]
6. breast cancer genomes from CHEK2 c.1100delC mutation carriers lack somatic TP53 mutations and display a unique structural variant size distribution profile.
Smid M; Schmidt MK; Prager-van der Smissen WJC; Ruigrok-Ritstier K; Schreurs MAC; Cornelissen S; Garcia AM; Broeks A; Timmermans AM; Trapman-Jansen AMAC; Collée JM; Adank MA; Hooning MJ; Martens JWM; Hollestelle A
Breast Cancer Res; 2023 May; 25(1):53. PubMed ID: 37161532
[TBL] [Abstract] [Full Text] [Related]
7. The role of p53 and ki67 in predicting clinical outcome in breast cancer patients.
Lalkota BP; Srinivasa BJ; Swamy MV; Hazarika D; Jeet BM; Jyothi K; Ghosh M; Sayeed SM; Nasiruddin M; Naik R
J Cancer Res Ther; 2023; 19(2):208-213. PubMed ID: 37006059
[TBL] [Abstract] [Full Text] [Related]
8. ER-/PR+ breast cancer is controlled more effectively with an inflammatory inhibitor than hormonal inhibitor.
Song C; Kendi AT; Shim JY; Jung D; Kang PS; Lowe VJ; Lee S
Breast Cancer; 2023 May; 30(3):436-452. PubMed ID: 36859733
[TBL] [Abstract] [Full Text] [Related]
9. High PD-L2 Predicts Early Recurrence of ER-Positive breast cancer.
Chervoneva I; Peck AR; Sun Y; Yi M; Udhane SS; Langenheim JF; Girondo MA; Jorns JM; Chaudhary LN; Kamaraju S; Bergom C; Flister MJ; Hooke JA; Kovatich AJ; Shriver CD; Hu H; Palazzo JP; Bibbo M; Hyslop T; Nevalainen MT; Pestell RG; Fuchs SY; Mitchell EP; Rui H
JCO Precis Oncol; 2023 Jan; 7():e2100498. PubMed ID: 36652667
[TBL] [Abstract] [Full Text] [Related]
10. Characterisation of the immune microenvironment of primary breast cancer and brain metastasis reveals depleted T-cell response associated to ARG2 expression.
Giannoudis A; Varešlija D; Sharma V; Zakaria R; Platt-Higgins A; Rudland PS; Jenkinson MD; Young LS; Palmieri C
ESMO Open; 2022 Dec; 7(6):100636. PubMed ID: 36423363
[TBL] [Abstract] [Full Text] [Related]
11. Spatial and Quantitative Analysis of Tumor-Associated Macrophages: Intratumoral CD163-/PD-L1+ TAMs as a Marker of Favorable clinical outcomes in Triple-Negative breast cancer.
Shinohara H; Kobayashi M; Hayashi K; Nogawa D; Asakawa A; Ohata Y; Kubota K; Takahashi H; Yamada M; Tokunaga M; Kinugasa Y; Oda G; Nakagawa T; Onishi I; Kinowaki Y; Kurata M; Ohashi K; Kitagawa M; Yamamoto K
Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36362023
[TBL] [Abstract] [Full Text] [Related]
12. High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER
Palafox M; Monserrat L; Bellet M; Villacampa G; Gonzalez-Perez A; Oliveira M; Brasó-Maristany F; Ibrahimi N; Kannan S; Mina L; Herrera-Abreu MT; Òdena A; Sánchez-Guixé M; Capelán M; Azaro A; Bruna A; Rodríguez O; Guzmán M; Grueso J; Viaplana C; Hernández J; Su F; Lin K; Clarke RB; Caldas C; Arribas J; Michiels S; García-Sanz A; Turner NC; Prat A; Nuciforo P; Dienstmann R; Verma CS; Lopez-Bigas N; Scaltriti M; Arnedos M; Saura C; Serra V
Nat Commun; 2022 Sep; 13(1):5258. PubMed ID: 36071033
[TBL] [Abstract] [Full Text] [Related]
13. estrogen receptor Alpha Gene Amplification Is an Independent Predictor of Long-Term outcome in Postmenopausal Patients with Endocrine-Responsive Early breast cancer.
Singer CF; ; Holst F; Steurer S; Burandt EC; Lax SF; Jakesz R; Rudas M; Stöger H; Greil R; ; Sauter G; Filipits M; ; Simon R; Gnant M;
Clin Cancer Res; 2022 Sep; 28(18):4112-4120. PubMed ID: 35920686
[TBL] [Abstract] [Full Text] [Related]
14. Characterizing Clinicopathologic Features of estrogen receptor-Positive/Progesterone receptor-Negative breast cancers.
Fei F; Siegal GP; Wei S
Clin Breast Cancer; 2022 Oct; 22(7):e788-e797. PubMed ID: 35915022
[TBL] [Abstract] [Full Text] [Related]
15. Does concomitant ductal carcinoma in situ affect the clinical outcome in breast cancer patients with invasive ductal carcinoma: An Asian perspective.
Lee WP; Shetty SS; Seah CMJ; Tan PT; Tan SM
Cancer Rep (Hoboken); 2022 Sep; 5(9):e1646. PubMed ID: 35892151
[TBL] [Abstract] [Full Text] [Related]
16. High AUF1 level in stromal fibroblasts promotes carcinogenesis and chemoresistance and predicts unfavorable prognosis among locally advanced breast cancer patients.
Al-Tweigeri T; AlRaouji NN; Tulbah A; Arafah M; Aboussekhra M; Al-Mohanna F; Gad AM; Eldali AM; Elhassan TA; Aboussekhra A
Breast Cancer Res; 2022 Jul; 24(1):46. PubMed ID: 35821051
[TBL] [Abstract] [Full Text] [Related]
17. Molecular crosstalk between CUEDC2 and ERα influences the clinical outcome by regulating mitosis in breast cancer.
Roy S; Saha S; Dhar D; Chakraborty P; Singha Roy K; Mukherjee C; Gupta A; Bhattacharyya S; Roy A; Sengupta S; Roychoudhury S; Nath S
Cancer Gene Ther; 2022 Nov; 29(11):1697-1706. PubMed ID: 35732909
[TBL] [Abstract] [Full Text] [Related]
18. Targeting LIPA independent of its lipase activity is a therapeutic strategy in solid tumors via induction of endoplasmic reticulum stress.
Liu X; Viswanadhapalli S; Kumar S; Lee TK; Moore A; Ma S; Chen L; Hsieh M; Li M; Sareddy GR; Parra K; Blatt EB; Reese TC; Zhao Y; Chang A; Yan H; Xu Z; Pratap UP; Liu Z; Roggero CM; Tan Z; Weintraub ST; Peng Y; Tekmal RR; Arteaga CL; Lippincott-Schwartz J; Vadlamudi RK; Ahn JM; Raj GV
Nat Cancer; 2022 Jul; 3(7):866-884. PubMed ID: 35654861
[TBL] [Abstract] [Full Text] [Related]
19. Type I IFN stimulates IFI16-mediated aromatase expression in adipocytes that promotes E
Ka NL; Lim GY; Kim SS; Hwang S; Han J; Lee YH; Lee MO
Cell Mol Life Sci; 2022 May; 79(6):306. PubMed ID: 35593921
[TBL] [Abstract] [Full Text] [Related]
20. Expression of NOTCH1, NOTCH4, HLA-DMA and HLA-DRA is synergistically associated with T cell exclusion, immune checkpoint blockade efficacy and recurrence risk in ER-negative breast cancer.
Liu D; Hofman P
Cell Oncol (Dordr); 2022 Jun; 45(3):463-477. PubMed ID: 35543859
[TBL] [Abstract] [Full Text] [Related]
[Next]
